Cryptococcus neoformans isolates from transplant recipients are not selected for resistance to calcineurin inhibitors by current immunosuppressive regimens

J Clin Microbiol. 2005 Jan;43(1):464-7. doi: 10.1128/JCM.43.1.464-467.2005.

Abstract

The immunosuppressants tacrolimus (FK506) and cyclosporine A inhibit calcineurin and have potent antifungal activity. In this study, 24% of Cryptococcus neoformans isolates from solid-organ transplant patients exhibited altered sensitivity to these drugs, which may have an impact on the infectious course but does not appear to be the consequence of immunosuppressive therapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Calcineurin / metabolism
  • Calcineurin Inhibitors*
  • Cryptococcosis / microbiology
  • Cryptococcus neoformans / drug effects*
  • Cryptococcus neoformans / isolation & purification
  • Cyclosporine / pharmacology*
  • Cyclosporine / therapeutic use
  • Drug Resistance, Fungal*
  • Humans
  • Immunosuppressive Agents / pharmacology*
  • Immunosuppressive Agents / therapeutic use
  • Microbial Sensitivity Tests
  • Organ Transplantation / adverse effects*
  • Tacrolimus / pharmacology*
  • Tacrolimus / therapeutic use

Substances

  • Calcineurin Inhibitors
  • Immunosuppressive Agents
  • Cyclosporine
  • Calcineurin
  • Tacrolimus